---
title: "MedWellAI, Inc. SEC 10-Q Report"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276638041.md"
description: "MedWellAI, Inc. has released its Form 10-Q report for Q4 2025, indicating a strategic shift from digital asset mining to AI-driven healthcare solutions. Key financial highlights include a decrease in commission and online sales revenues, while product sales surged to $522,798. The net loss attributable to shareholders improved to $939,397. The company operates through subsidiaries like MedWell USA and MedWell Facilities, focusing on pharmaceutical distribution and real estate in healthcare. Future plans include expanding AI-driven healthcare solutions and consolidating preferred stock."
datetime: "2026-02-23T19:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276638041.md)
  - [en](https://longbridge.com/en/news/276638041.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276638041.md)
---

# MedWellAI, Inc. SEC 10-Q Report

MedWellAI, Inc., formerly known as Integrated Ventures, Inc., has released its Form 10-Q report for the fourth quarter of 2025. The report highlights the company's strategic shift from digital asset mining to AI-driven healthcare and wellness solutions, alongside significant changes in its financial and operational performance.

**Financial Highlights**

-   **Revenues from commissions:** $2,623 for the three months ended December 31, 2025, decreased from $133,272 in the same period in 2024, due to a shift in focus to product sales.
-   **Revenues from online sales:** $394 for the three months ended December 31, 2025, decreased from $9,589 in the same period in 2024, as the company exited online sales due to regulatory hurdles.
-   **Revenues from product sales:** $522,798 for the three months ended December 31, 2025, increased from $0 in the same period in 2024, reflecting a strategic shift to product sales.
-   **Rental income:** $22,500 for the three months ended December 31, 2025, increased from $0 in the same period in 2024, due to a new sublease agreement.
-   **Net Loss Attributable to shareholders:** $939,397 for the six months ended December 31, 2025, improved from $1,889,958 in the same period in 2024, as the company transitioned from digital asset mining to health and wellness.

**Business Highlights**

-   **Company Overview:** MedWellAI, Inc. is a diversified holdings company focused on AI-driven healthcare and wellness solutions. The company operates through subsidiaries like MedWell USA, a B2B e-commerce platform for pharmaceutical distribution, and MedWell Facilities, which focuses on real estate opportunities in the health and wellness sector.
-   **Business Focus Shift:** The company has shifted its focus from digital asset mining to product sales in the healthcare and wellness industry, particularly GLP medications for weight loss and diabetes management.
-   **Subsidiary Operations:** MedWell USA operates an AI-powered ordering system for pharmaceutical products, providing real-time inventory tracking and smart suggestions for healthcare providers. MedWell Facilities is dedicated to developing real estate opportunities to attract healthcare providers and wellness clinic operators.
-   **Acquisition:** On August 29, 2024, the company acquired 51% of the membership interests in Healthy Lifestyle USA LLC, a Florida-based company, through its subsidiary MedWell Direct.
-   **Revenue Segments:** The company reported revenue from product sales, commissions, and rental income. Product sales have become a significant focus, with substantial increases in revenue compared to the previous year.
-   **Operational Changes:** The company exited online sales due to regulatory hurdles and discontinued its digital asset mining operations, marking a strategic shift towards healthcare and wellness.
-   **Recent Developments:** Effective August 1, 2025, the company consolidated its Series C and D Preferred Stock into a single series of convertible preferred stock, retiring $2,133,081 in accrued and unpaid dividends.
-   **Future Outlook:** The company aims to continue its focus on AI-driven healthcare solutions and expand its presence in the health and wellness industry, leveraging its subsidiaries to drive growth and operational efficiency.

SEC Filing: MedWellAI, Inc. \[ MWAI \] - 10-Q - Feb. 23, 2026

### Related Stocks

- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [MNMD.US](https://longbridge.com/en/quote/MNMD.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [BMY Stock Rises as Bristol Myers Brings Anthropic's Claude AI to 30,000 Employees](https://longbridge.com/en/news/287076466.md)
- [Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program](https://longbridge.com/en/news/287222906.md)